Sepideh Peivandi, Hamed Jafarpour, Mina Abbaspour and Aghdas Ebadi
. Changes in hormonal profile and seminal parameters with use of aromatase inhibitors in management of infertile men with low testosterone to estradiol ratios. Fertil Steril 98, 48–51, 2012.
Haider H, Solanki KS, Pal G, Singh MK, Kothari JS, Agarwal VK. Process for the preparation of letrozole. WO/2007/054964, PCT/IN2006/000337, 2007. https://patentscope.wipo.int › search › detail.
Haynes BP, Jarman M, Dowsett M, Mehta A, Lonning PE, Griggs LJ, Jones A, Powles T, Stein R, Coombes RC. Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3
1. Nauck MA, Homberger E, Siegel EG et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63: 492-498, 1986.
2. Nauck MA, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (noninsulin- dependent) diabetes. Diabetologia 29: 46-52, 1986.
3. Vildagliptin - summary of product characteristics, 2012.
4. He Y-L. Clinical pharmacokinetics and pharmacodynamics of
receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab 19: 524-536, 2017.
7. Malone J, Trautmann M, Wilhelm K, Taylor K, Kendall DM. Exenatide once weekly for the treatment of type 2 diabetes. Expert Opin Investig Drugs 18:359-367, 2009.
8. Knop FK, Brønden A, Vilsbøll T. Exenatide: pharmacokinetics, clinical use, and future directions. Expert Opin Pharmacother 18: 555-571, 2017.
9. Abd El Aziz MS, Kahle M, Meier JJ, Nauck MA. A meta-analysis comparing clinical effects of short- or
14. Eng CM, Smallwood LH, Rainiero MP, Lahey M, Ward SR, Lieber RL. Scaling of muscle architecture and fiber types in the rat hindlimb. J Exp Biol 211: 2336-2345, 2008.
15. Hu N, Xie S, Liu L et al. Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats. Drug Metab Dispos 39: 419-425, 2011.
16. Dupouy VM, Ferre PJ, Uro-Coste E, Lefebvre HP. Time course of COX-1 and COX-2 expression during ischemia-reperfusion in rat skeletal muscle. J
Gulsah Kaner, Kubra Tel Adiguzel and Nilgun Seremet Kurklu
. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49: 71-87, 2010.
24. Zhou SS, Li D, Chen NN, Zhou Y. Vitamin paradox in obesity: Deficiency or excess? World J Diabetes 6: 1158-1167, 2015.
25. Bird JK, Ronnenberg AG, Choi SW, Du F, Mason JB, Liu Z. Obesity is associated with increased red blood cell folate despite lower dietary intakes and serum concentrations. J Nutr 145: 79-86, 2015.
26. Pfeiffer CM, Sternberg MR, Fazili Z et al. Folate status and concentrations of serum folate forms in the US population
Johad Khoury, Elias Andrawus, Boaz Y. Bishop and Zaher S. Azzam
, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30, 239–245, 1981.
Soon D, Kothare PA, Linnebjerg H, Park S, Yuen E, Mace KF, Wise SD. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol 46, 1179–1187, 2006.
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes
Sona Scsukova, Mlynarcikova A. Bujnakova, A. Kiss and E. Rollerova
drug carriers. Adv Clin Exp Med 24, 749-758, 2015.
Oberdoster G. Safety assessment for nanotechnology and nanomedicine: concept of nanotoxicology. J Intern Med 267, 89-105, 2009.
Patel T, Zhou J, Piepmeier JM, Saltzman WM. Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev 163, 93-99, 2012.
Pelham RW, Nix LC, Chavira RE, Cleveland MVB, Stetson P. Clinical trial: si ngle- and multiple-dose pharmacokinetics of polyethylene glycol (PEG-3350) in young and elderly subjects. Aliment
Aleksandra Kubiak-Mlonka, Ewelina Ziółkowska, Tadeusz Robak and Anna Korycka-Wołowiec
Robak T Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly Expert Opin Drug Metab Toxicol 2015 11 1371 91
 Wilson WH, O’Connor OA, Czuczman MS, et al. Navitoclax, a targeted high affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010;11:1149-59. 21094089 10.1016/S1470-2045(10)70261-8 Wilson WH O’Connor OA Czuczman MS et al Navitoclax, a targeted high
, Barlow KB, Nobrega JN, Kapur S. Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models. Int J Neuropsychopharmacol 14, 1165–1178, 2011.
Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 63 (Suppl 13), 5–11, 2002.
Nomikos GG, Tham CS, Fibiger HC, Svensson TH. The puta in rat medial prefrontal cortex and lateral tive atypical antipsychotic drug amperozide preferentially increases c-fos expression septum
Henu Kumar Verma, Saikrishna Lakkakula and Bhaskar V.K.S. Lakkakula
pharmacokinetics of HU indicate that the renal impairment results in increased systemic exposure and decreased urinary recovery of the drug [ 16 ]. Some patients receiving HU therapy showed mild albuminuria, with an increase in white cells and granular casts, as well as occasional red cells, in the urine [ 76 ]. However, the BABY HUG trial demonstrated that HU is associated with better urine-concentrating ability and less renal enlargement, in addition to improvement in overall renal function [ 58 ]. Studies in animal models revealed that that HU therapy inhibits spermatogenesis